Jeffrey Trigilio

Jeffrey Trigilio, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Cullinan Therapeutics, Inc. and XOMA Royalty Corp. Between 12 January 2021 and 14 July 2026, the trades on record add up to 27 filings.

The open-market side counts 1 purchase for €39k alongside 13 sales for €592k. Netting one side against the other leaves €553k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 8 share grants and 4 option exercises.

The latest filing, published on 14 July 2026, reports a transaction in XOMA Royalty Corp. The last purchase on record was published on 14 January 2021, which is 2,125 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.